title: Selective serotonin reuptake inhibitors and pregnancy: A review of maternal, fetal and neonatal risks and benefits.
abstract: Depression is common in women of childbearing age. Whereas non-pharmacological interventions are recommended as first line interventions, pharmacological treatment may be required. Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressants in pregnancy. Ideally, discussion of the risks and benefits of SSRI use in pregnancy should occur prior to pregnancy. The potential risks of psychotropic medications need to be balanced against the risks associated with untreated psychiatric conditions and the discontinuation of necessary medications.
authors.affiliation: Department of Obstetrics and Gynaecology, University College Cork, Cork University Maternity Hospital, Wilton, Cork, Ireland.
authors.forename: Zbigniew
authors.initials: Z
authors.lastname: Marchocki
authors.affiliation: Department of Obstetrics and Gynaecology, University College Cork, Cork University Maternity Hospital, Wilton, Cork, Ireland.
authors.forename: Noirin E
authors.initials: NE
authors.lastname: Russell
authors.affiliation: Department of Obstetrics and Gynaecology, University College Cork, Cork University Maternity Hospital, Wilton, Cork, Ireland.
authors.forename: Keelin O'
authors.initials: KO
authors.lastname: Donoghue
keywords: Drugs (medication); clinical pharmacology; high-risk pregnancy; neonatal medicine